»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China lenvatinib Mesylate CAS 857890-39-2 E7080 Mesylate manufacturer

5th

Gold Index: 89140

You are here: home  > New products  > lenvatinib Mesylate CAS 857890-39-2 E7080 Mesylate

lenvatinib Mesylate CAS 857890-39-2 E7080 Mesylate 

Payment Terms: T/T,L/C,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: MOS 23
Production Capacity: 200KG/MONTH
Delivery Date: within 7 days
CAS: 857890-39-2
Content: 98%min
Synonyms 2: E7080 Mesylate
Means of Transport: Ocean,Land,Air
Packing: As per request of clients
Name: lenvatinib Mesylate
Molecular Formula: C21H19ClN4O4.CH4O3S
Brand: MOSINTER
Product Categories: API

FGF receptor antagonist

lenvatinib Mesylate CAS 857890-39-2 E7080 Mesylate


Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.



Usage

E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively.

Definition

ChEBI: A methanesulfonate salt obtained by reaction of lenvatinib with one molar equivalent of methanesulfonic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to r dioiodine.


PACKING 


PACKING


Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.


Lenvatinib is approved (since 2015) for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine).


In May 2016, the US FDA approved it (in combination with everolimus) for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy


Hypertension (high blood pressure) was the most common side effect in studies (73% of patients, versus 16% in the placebo group), followed by diarrhoea (67% vs. 17%) and fatigue (67% vs. 35%).Other common side effects included decreased appetite, hypotension (low blood pressure), thrombocytopenia(low blood platelet count), nausea, muscle and bone pain.

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: